Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
E: investor.relations@sanofi.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
markets
Globalisation declining? Not in investor portfolios
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,775.00 | 4.40 | 0.05% |
| CAC 40 | 7,714.66 | 29.98 | 0.39% |
| DAX 40 | 23,559.08 | 42.85 | 0.18% |
| Dow JONES (US) | 42,197.79 | 769.83 | -1.79% |
| FTSE 100 | 8,867.01 | 16.38 | 0.19% |
| HKSE | 24,087.35 | 194.79 | 0.82% |
| NASDAQ | 19,406.83 | 255.66 | -1.30% |
| Nikkei 225 | 38,311.33 | 477.08 | 1.26% |
| NZX 50 Index | 12,690.13 | 137.26 | 1.09% |
| S&P 500 | 5,976.97 | 68.29 | -1.13% |
| S&P/ASX 200 | 8,548.40 | 1.00 | 0.01% |
| SSE Composite Index | 3,388.73 | 11.73 | 0.35% |